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Aim To assess whether an adenoviral vector carrying the 
bone morphogenetic protein genes (Ad.BMP-2) can trans-
duce human muscle tissue and direct it toward osteogenic 
differentiation within one hour.
Methods This in vitro study, performed at the Department 
of Molecular Biology, Faculty of Science, Zagreb from 2012 
to 2017, used human muscle tissue samples collected dur-
ing anterior cruciate ligament reconstructions performed 
in St Catherine Hospital, Zabok. Samples from 28 patients 
were transduced with adenoviral vector carrying firefly lu-
ciferase cDNA (Ad.luc) by using different doses and times 
of transduction, and with addition of positive ions for 
transduction enhancement. The optimized protocol was 
further tested on muscle samples from three new patients, 
which were transduced with Ad.BMP-2. Released bone 
morphogenetic protein 2 (BMP-2) levels in osteogenic me-
dium were measured every three days during a period of 
21 days. Expression of osteogenic markers was measured 
at day 14 and 21. After 21 days of cultivation, muscle tis-
sue was immunohistochemically stained for collagen type 
I detection (COL-I).
Results The new transduction protocol was established us-
ing 108 plaque-forming units (P < 0.001) as an optimal dose 
of adenoviral vector and 30 minutes (P < 0.001) as an opti-
mal contact time. Positive ions did not enhance transduc-
tion. Samples transduced with Ad.BMP-2 according to the 
optimized protocol showed enhanced expression of osteo-
genic markers (P < 0.050), BMP-2 (P < 0.001), and COL I.
Conclusion This study confirms that Ad.BMP-2 can trans-
duce human muscle tissue and direct it toward osteogenic 
differentiation within 30 minutes.
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Regenerative medicine looks for the ways to stimulate 
the inherent ability of our body to regenerate damaged 
tissue by activating or promoting natural healing pro-
cesses, thus lowering the number of needed surgical or 
other medical interventions. It focuses on the interaction 
of cells, biological signals, and the environment (1). One 
of the most important topics in orthopedics is bone re-
generation. Essential components needed for bone re-
generation are osteogenic cells, osteoinductive growth 
factors, and an osteoconductive structure in the local en-
vironment (2,3). Various human cells have the potential 
to differentiate toward osteolineage cells. For example, 
bone-marrow derived mesenchymal stem cells (4) and 
stem cells derived from anterior cruciate ligament (ACL) 
remnant have been used to promote bone healing (5). 
Moreover, the insights into the creation of heterotopic 
bone (6) and the disease fibrodysplasia ossificans pro-
gressiva (7) have revealed a significant ability of human 
muscles to create bone. Muscle tissue contains various 
populations of progenitor cells: satellite, non-satellite, 
and perivascular cells. Non-satellite mesenchymal pro-
genitors and perivascular cells play the main role in het-
erotopic bone formation (8).
Although human muscle-derived cells can enhance bone 
regeneration (9), they often lack sufficient biological stim-
uli by growth factors, the most potent of which are bone 
morphogenetic proteins (BMP) -2, -4, and -7 (10-12). Suc-
cessful osteogenesis depends on appropriate spatial and 
temporal expression of BMPs. BMP-2 has been used to pro-
mote bone regeneration (4,5,9), but it is soluble and dis-
appears soon after implantation, so that many researchers 
have sought the delivery system to retain BMP-2 at the tar-
get site. This search led to the BMP-2-expressing viral vec-
tors, as a concept representing gene therapy. The goal of 
gene therapy is to implement genetic material into cells, 
thus providing sufficient concentration of the missing sub-
strate and alleviating the disease symptoms (13). This new 
genetic material is transferred to cells using virus vectors 
carrying genes needed for treatment.
In recent years, many of these novel techniques have been 
developed for the treatment of musculoskeletal diseases, 
both for healing of bone and soft tissues (1,14-16). How-
ever, these methods have their limitations and need to be 
further improved. An example of this kind of treatment 
is the conventional ex vivo gene therapy, which was the 
initial modality of gene therapy and the first one used 
in clinical trials on humans (17). It consists of several 
steps: harvesting of cells from the body, in vitro cul-
tivation, infection of cells with virus vectors, and replanta-
tion of genetically modified cells back to the donor (13). 
Such a strategy has been proven successful, although not 
ideal for application during orthopedic procedures. Tis-
sue transportation and cultivation in a laboratory requires 
two-steps surgical procedures, making the whole process 
expensive, long lasting, and inconvenient for the patient. 
To avoid such a complicated procedure, the expedited 
ex vivo strategies have been developed. The idea behind 
them is to perform a successful gene therapy inside the 
operating theater during a single procedure and without 
the need for extensive tissue cultivation. Several studies of 
gene therapy used for bone and cartilage healing proved 
this to be possible, but the whole process lasted minimally 
two hours (4,18). Although this is a significant step forward 
compared with the conventional ex vivo gene therapy, the 
average duration of orthopedic procedures is often short-
er than two hours. Consequently, these strategies cannot 
be clinically implemented in some of the most common 
orthopedic procedures, such as ACL reconstruction, and 
need optimization. The efficiency of gene therapy can be 
improved by enhancing the cell transduction with ade-
noviral vectors through prevention of electrostatic rejec-
tion between the negative ions of cell surfaces and ad-
enoviruses (19-21), development of new serotypes of 
adenoviruses (22), and changing virus envelope proteins 
to improve tissue specificity and cell surface binding (23). 
Owing to the binding ability between negative cell sur-
face charge and adenovirus vectors, positive La3+ increase 
the percentage of transduced cells and the transgenic ex-
pression per cell (21).
The aim of our study was to create a model of gene ther-
apy for bone regeneration that could be performed as a 
one-step procedure, with abundant and easily harvested 
tissue, and the surgery duration in reasonable boundaries, 
thus lowering the chances of complications. We hypoth-
esized that Ad.BMP-2 was capable to transduce human 
muscle tissue and direct it toward osteogenic differentia-
tion within a period shorter than one hour.
MATERIALS AND METHODS
Study design
This single center in vitro analytic study was performed at 
the Department of Molecular Biology, Faculty of Science, 
University of Zagreb from 2012 to 2017. The study was ap-
proved by the Ethics Committee of St. Catherine’s Hospi-
tal on November 7, 2012 (07112012). The muscle samples 
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were collected during ACL reconstructions performed in 
St Catherine Hospital, Zabok from 2012 to 2016. The study 
involved 31 patients (between 18 and 55 years) who pre-
viously completed informed consent forms for joining the 
study and data publication. We divided our study into four 
phases. In the first three phases we used Ad.Luc as a stan-
dard for measuring viral transduction of muscle cells. In 
the first phase we estimated the optimal dose of Ad.Luc 
for human muscle tissue transduction. In the second 
phase we determined the optimal time in which this dose 
of Ad.Luc should be in contact with the human muscle 
tissue. The third phase included testing whether different 
concentrations of La3+ and Ca2+ cations in combination 
with the optimal dose and time affect viral transduction 
of the cells. In the fourth phase, we used Ad.BMP-2, fol-
lowing an optimized protocol from the first three phases. 
We measured the gene expression of BMP-2 every 3 days 
during a period of 21 days and osteogenic markers runt-
related transcription factor (RUNX2), bone sialoprotein (BSP), 
and dentin matrix protein 1 (DMP-1) on day 14 and 21. We 
also immunohistochemically detected collagen type I 
(COL-I) on day 21.
Tissue samples
The muscle samples were collected during ACL reconstruc-
tions performed in St Catherine Hospital. Muscle tissue was 
removed from the tendon muscular part and transported 
into Dulbecco’s Modified Eagle Medium (DMEM)-high glu-
cose (Lonza, Basel, Switzerland) supplemented with 10% 
fetal bovine serum (FBS) (Gibco Laboratories, Gaithersburg, 
MD, USA) and 1% penicillin (pen) and streptomycin (strep) 
(Invitrogen, Carlsbad, CA, USA).
Vectors
We used first generation adenoviruses (ΔE1, ΔE3), serotype 
5, carrying human BMP-2 (Ad.BMP-2) and firefly luciferase 
cDNA (Ad.Luc) under the transcriptional control of the hu-
man cytomegalovirus (24). Adenoviruses were kindly do-
nated by Professor Christopher H. Evans (Harvard Medical 
School, Boston, MA, USA). Vectors were propagated in HEK-
293 cells and further purified using cesium chloride den-
sity gradient, followed by dialysis. Viral stocks were stored 
in 10% glycerol at −80°C. The viral particles concentration 
was measured by optical density measurement (Ad.BMP-2, 
2.42 × 1012 viral particles/mL ±0.25; Ad.Luc, 1.42 × 1012 vi-
ral particles/mL ±0.32), while the number of infective viral 
particles was estimated by virus plaque assay (Ad.BMP-2, 
7.6 × 109 PFU/mL; Ad.Luc, 6.1 × 109) (25).
Phase 1: determination of optimal viral dose
Muscle tissue (8 patients) was cut into pieces (mass 50 
μg) and transferred into 500 μL of DMEM into 24 well 
plates. The medium was removed and the samples trans-
duced with 0, 105, 106, 107, and 108 plaque-forming units 
(PFU). 20 μL of appropriate viral dilution was dropped di-
rectly on the samples and incubated for 1 h at 37°C sup-
plemented with 5% CO2. Following incubation, 1 mL of 
DMEM was added to each sample and returned to the 
incubator for another hour. Finally, DMEM was aspirat-
ed, and the samples were washed three times in 2 mL 
of phosphate-buffered saline (PBS). Furthermore, 1 mL of 
fresh medium was added, and 72 h later total proteins 
were isolated and luciferase assay performed. For positive 
control, 108 PFU (20 μL) was directly added onto the mus-
cle sample, the tissue was not washed after 1 h in PBS, 
only DMEM was added. The tissue samples stayed in con-
tact with the virus until the 72 h endpoint.
Phase 2: determination of the optimal contact time
Muscle tissue (10 patients) was cut and processed as previ-
ously described, followed by transduction with previously 
determined optimal viral dose. The samples were incubat-
ed for 0, 15, 30, 60 min, and 72 h at 37°C supplemented 
with 5% CO2. Following the incubation period, the samples 
were processed in an identical manner as previously de-
scribed and, after 72 h total proteins were isolated and lu-
ciferase assay was performed.
Phase 3: the effect of lanthanum and calcium ions on 
transduction
Muscle tissue (10 patients) was transduced with the pre-
viously determined optimal dose and contact time, with 
the addition of ions as follows: Ad.Luc; Ad.Luc +0.2 mM 
La3+; Ad.Luc +5 mM Ca2+; and Ad.Luc +0.2 mM La3+ + 5 
mM Ca2+. The samples were washed in PBS and incubated 
for 72 h in an incubator, followed by protein isolation and 
luciferase assay.
Total protein extraction and luciferase assay
Total protein extracts were obtained using CelLytic M (Sig-
ma-Aldrich, Taufkirchen, Germany). Briefly, DMEM was as-
pirated; the samples were washed three times in 2 mL of 
PBS, frozen in liquid nitrogen, and homogenized with a 
mortar and pestle. 300 μL of CelLytic M was added to 
each sample. Protein concentration was determined 
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using the bicinchoninic acid protein assay kit (Thermo 
Fisher Scientific, Waltham, MA, USA) according to manu-
facturer’s instructions. In Opaque 96-Well Microplate, 100 
μL of total protein extract was mixed with 100 μL of lu-
ciferase assay buffer (1 mM adenosine triphosphate, 0.25 
mM luciferin, 1% bovine serum albumin, 8 mM MgCl2, 0.4 
mM dithiothreitol, 1 mM ethylene glycol-bis(β-aminoethyl 
ether)-N,N,N’,N’-tetraacetic acid) and luciferase enzyme. 
Luminescence was measured by using microplate reader 
(Victor Multilabel X, Perkin Elmer, Waltham, MA, USA).
Phase 4: the application of optimized transduction 
protocols for enhanced osteodifferentiation of muscle 
tissue using AD.BMP 2
Every muscle tissue (3 patients) was cut into 4 × 50 μg piec-
es and separated into 2 groups (two samples in one group) 
to evaluate its osteogenic response to transduction with 
Ad.BMP-2. One group of doubled samples was transduced 
with Ad.BMP 2 viral vector by applying the previously op-
timized protocol and the other group of doubled samples 
was not transduced. All samples were thoroughly washed 
in PBS and incubated in osteogenic medium (Minimum 
Essential Medium – Alpha Eagle, 10% FBS, 1% pen/strep, 
50 μg/mL ascorbic acid, and 10 mM β-glycerophosphate) 
over a period of 14 and 21 days.
The osteogenic media were replaced every 3 days, and re-
leased BMP-2 levels were measured with an ELISA kit (R&D 
Systems, Minneapolis, MN, USA) according to the manu-
facturer’s protocol. The expression of osteogenic markers 
RUNX2, BSP, and DMP1 was measured by real-time quanti-
tative PCR (qPCR) at day 14 and 21. After 21 days of cultiva-
tion, muscle tissue was prepared for immunohistochemi-
cal staining and COL-I detection.
Gene expression studies
Total RNA (2 μg) was isolated using TRIzol reagent (Invit-
rogen) according to manufacturer’s instructions follow-
ing DNase I treatment (New England Biolabs, Ipswich, 
MA, USA). cDNA was synthetized under the following 
conditions: 10 min at room temperature, 1 h at 42°C, 5 
min at 99°C, and 5 min at 5°C. The expression of RUNX2 
(Mm00501584_ m1), DMP-1 (Ms01009391_g1), and BSP 
(Hs00173720_m1) on days 14 and 21 was analyzed with 
TaqMan® Gene Expression Assays (Thermo Fisher Scien-
tific). QPCR was performed on the 7500 Fast PCR system 
(Applied Biosystems) under the following conditions: 
10 min at 95°C for 1 cycle, 15 s at 95°C, and 1 min-
ute at 60°C for 40 cycles. Expression levels were normalized 
to GAPDH (Hs02758991_g1), and relative gene expressions 
were assessed with ΔΔCt method.
Immunohistochemical detection of COL-I
The samples were fixed in 4% buffered paraformaldehyde 
following decalcification in 14% EDTA solution. After equil-
ibration in PBS buffered with 30% sucrose for 48 h, the 
samples were embedded in Tissue-Tek (O.C.T. compound, 
Sakura, CA, USA) and frozen at −80°C. 10 μm-thick sections 
(cryostat, Leica, Wetzlar, Germany) were mounted on Su-
perfrost plus slides (Thermo Fisher Scientific). COL-I was 
detected using EnVision Detection Systems Peroxidase/
DAB, Rabbit/Mouse (Dako/Agilent, Santa Clara, CA, USA) 
and anti-collagen I (Abcam, Cambridge, UK), as previously 
described (26). Human bone was used as a positive control. 
It was embedded in paraffin, followed by deparaffinization, 
and thus it was not designated for immunohistochemical 
comparison.
Statistical analysis
The nature of the experiment (preparation of large num-
ber of high-concentration adenoviral vectors) was prohibi-
tive of larger sample sizes, therefore the sample size was 
defined arbitrarily. Normality of the data distribution was 
tested by the Shapiro-Wilks test. Data are presented as a 
mean ± standard deviation (SD). Repeated measures ANO-
VA, one-way ANOVA, and t test were used for descriptive 
statistical analysis. Post hoc power analysis was performed 
for the DMP-1, for day 1 and 14 (T1 and T14), using repeat-
ed measurements method, with the following parame-
ters: meanT1 1.11, SDT1 0.61; meanT14 80.62, SDT14 54.61. 
Entering these values to G*power software (http://www.
gpower.hhu.de/) yielded the effect size of 1.46, which in 
turn yielded the overall β of 0.85. The level of significance 
was set at P < 0.050. Statistical analysis was performed us-
ing the TIBC Statistica version, 13.3 statistical model (TIBCO 
Software Inc. Palo Alto, CA, USA).
RESULTS
Phase 1: the optimal viral dose
The results are shown as relative light units per microgram 
of protein (RLU/μg). Muscle tissue not transduced with 
Ad.Luc (negative control) did not show any luciferase ac-
tivity. The positive control, muscle tissue transduced with 
the concentration of 108 PFU and incubated to protein 
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isolation 72 h later, showed the highest luciferase activ-
ity (mean 121.97 ± 98.55; P < 0.001 compared with nega-
tive control). Muscle tissue transduced with 105, 106, 107, 
and 108 PFU and incubated for 2 hours differed significant-
ly in luciferase activity. Since 108 PFU induced the high-
est luciferase activity compared with muscle tissue trans-
duced with different PFU and incubated for 2 hours (mean 
82.10 ± 68.33; P < 0.001), it was accepted as the optimal vi-
ral dose (Figure 1).
Phase 2: the optimal contact time
Negative control did not show any luciferase activity, while 
the positive control showed the highest luciferase activity 
(mean 213.3 ± 104.18, P < 0.001 compared with the nega-
tive control). Muscle tissue transduced with the optimal 
dose of Ad.Luc and incubated for 15 min showed lower 
luciferase activity than all other samples and the positive 
control, and higher luciferase activity than the negative 
control (52.20 ± 39.59, P < 0.001). The tissue incubated for 
30 min showed higher luciferase activity than the negative 
control and the tissue incubated for 15 min (91.73 ± 51.67, 
P < 0.001) but did not differ significantly from the tissue 
incubated for 60 min (128.21 ± 66.39; P = 0.187) (Figure 2). 
Therefore, the 30-min transduction was accepted as the 
optimal contact time.
Phase 3: the effect of lanthanum and calcium ions on 
transduction
Muscle tissue transduced with Ad.Luc infectivity 108 PFU 
and incubated for 72 h until protein isolation (positive con-
trol) showed higher luciferase activity than all other sam-
ples (mean 25.80 ± 5.82, P < 0.001). Since the rest of the 
samples did not show significant luciferase activity, we 
concluded that La3+ and Ca2+ ions did not improve trans-
duction (Figure 3).
Phase 4: the application of optimized transduction 
protocols for enhanced osteodifferentiation of muscle 
tissue using AD.BMP-2
Expression of BMP-2. Transduced muscle showed signifi-
cantly higher BMP-2 levels (P < 0.001) than non-transduced 
muscle. There was no difference in BMP-2 expression be-
tween all transduced samples at all time points. Looking at 
the absolute values, BMP-2 expression value in transduced 
muscles rapidly increased, peaked on day 12, and gradually 
decreased thereafter. Non-transduced muscle did not ex-
press BMP-2 until day 21, when low BMP-2 expression was 
observed (Figure 4).
Expression of osteogenic markers. Transduced muscle had 
significantly higher RUNX2 gene expression (P = 0.045 on 
day 14 and day 21) (Figure 5A) and DMP-1 gene expres-
FIGURE 1. Human muscle tissue transduced with different 
doses of adenoviral vector carrying the luciferase reporter 
gene (Ad.Luc). The results are expressed as relative light 
units per microgram of protein (RLU/μg) and presented as 
mean ± standard deviation, n = 8, *P < 0.001. Positive control 
(ctrl+), human muscle tissue transduced with Ad.Luc infectiv-
ity 108 plaque-forming units (PFU), was in contact with the 
virus for 72 h. Muscle tissue transduced for 2 hours with 0, 105, 
106, 107, and 108 PFU differed significantly in luciferase activity. 
Muscle tissue transduced with Ad.Luc 108 PFU showed the 
highest luciferase activity (82.10 ± 68.33; P < 0.001).
FIGURE 2. Human muscle tissue transduced with Ad.Luc 108 
under different contact times. The results are expressed as 
relative light units per microgram of protein (RLU/μg) and 
presented as mean ± standard deviation, n = 10, *P < 0.001. 
Positive control (ctrl+), human muscle tissue transduced with 
Ad.Luc infectivity 108 plaque-forming units (PFU), was in con-
tact with the virus for 72h. Muscle tissue transduced with the 
Ad.Luc 108 PFU and incubated for 30 and 60 min showed the 
highest luciferase activity.
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sion (P < 0.001 on day 14 and day 21) (Figure 5C) than non-
transduced muscle. BSP gene expression was significant-
ly higher in transduced muscle than in non-transduced 
muscle on day 14 (P = 0.016) but not on day 21 (P = 0.059) 
(Figure 5B).
Immunohistochemical detection of COL-I. After 21 days of 
cultivation in osteogenic medium, non-transduced tissue 
showed low COL-I expression, while transduced muscle 
tissue showed strong COL-I expression (Figure 6).
FIGURE 3. The effect of the addition of positive lanthanum ions 
(La3+) and calcium ions (Ca2+) on transduction enhancement. 
The results are expressed as relative light units per micro-
gram of protein (RLU/μg) and presented as mean ± standard 
deviation, n = 10. Positive control (ctrl+), human muscle tissue 
transduced with Ad.Luc infectivity 108 plaque-forming units 
(PFU), was in contact with the virus for 72 h. The presence of 
La3+ and Ca2+ did not improve the transduction.
FIGURE 4. Expression of bone morphogenetic protein 2 
(BMP-2) in native human muscle samples (black) and human 
muscle samples transduced with adenoviral vector carrying 
BMP-2 gene (Ad.BMP-2) (gray). BMP-2 levels in osteogenic me-
dium were measured every 3 days during 21 days by enzyme-
linked immunosorbent assay. The results are presented as 
mean ± standard deviation (n = 3), *P < 0.001 for transduced 
muscle under the optimized protocol compared with the non-
transduced muscle. Results of the muscle group are shown 
both graphically and numerically. Significantly higher BMP-2 
levels were observed in transduced muscle in comparison 
with non-transduced muscle. There was no difference in BMP 
expression between all transduced samples at all time points.
FIGURE 5. Expression of osteogenic differentiation markers 
in native human muscle samples (black) and human muscle 
samples transduced with adenoviral vector carrying BMP-2 
gene (Ad.BMP-2) (gray). Relative mRNA expression of (A) 
runt-related transcription factor (RUNX2), (B) bone sialoprotein 
(BSP), and (C) dentin matrix protein 1 (DMP-1) was determined 
by real-time quantitative polymerase chain reaction on day 
14 and 21. The results are presented as mean ± SD (n = 3), *P. 
Results of the muscle group in (C) are shown both graphically 
and numerically. The transduced muscle showed significantly 
higher RUNX2 expression (P = 0.045) (A) and DMP-1 gene ex-
pression than the non-transduced samples on days 14 and 21 
(P < 0.001) (C). BSP expression was significantly higher on day 
14 (P = 0.016) but not on day 21 (P = 0.059) (B).
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DISCUSSION
The results suggest that it is possible to develop a pioneer 
ex vivo gene therapy of human muscle tissue within 30 
minutes by using Ad.BMP-2 to induce osteogenic differen-
tiation. Translation of such strategies into clinical practice 
could enhance bone-tendon healing and prevent bone 
tunnel enlargement after ACL reconstruction.
During the ACL reconstruction, when the tendons are 
prepared for graft at the muscle end, the remaining 
part of the muscle tissue is removed and discarded. This 
part, however, could be preserved and used as a source 
of mesenchymal stem cells to stimulate tissue healing. 
Such a tissue could be used without any additional need 
for a donor site, thus reducing the potential donor site 
morbidity (ie, after obtaining bone marrow derived stem 
cells).
Adenoviral vectors have several advantages: they can be 
produced in a high titer, are highly infectious and able to 
infect cells in the resting and division phase, and their gene 
expression is transient due to episomal binding (27,28). Our 
results indicate that the highest dose of adenoviral vectors 
provides the best effect. Earlier studies also showed that 
the highest dose of adenoviral vectors improved transduc-
FIGURE 6. Immunohistochemical staining for collagen type I in muscle tissue transduced with Ad.BMP-2 under the optimized 
protocol. Positive staining is represented by brown color. Muscle tissue kept in osteogenic medium for 21 days was moderately 
stained (A). Transduced muscle tissue after 21 days of culture conditions was very strongly stained (C). Negative controls (-ctrl) were 
processed in the absence of suitable primary antibody (B),(D). Positive control was human bone (+ctrl) (E). Scale bar: 100 μm.
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tion when bone defects were repaired using genetically 
modified muscles (18). Two critical limitations affecting the 
process are low infection efficiency at low doses and cy-
totoxicity at high doses, not only due to viral infection but 
also due to transgene expression. We used high viral doses, 
and if even higher doses are used, cytotoxicity could over-
power the efficacy (29). As mentioned before, the nature 
of the experiment (preparations of large amounts of high 
concentration adenoviral vectors) was prohibitive of larger 
sample sizes.
Cell viability was not determined by MTT because cell 
abundance measurements, as MTT assay, work only if 
cell activity is constant, and cell activity can only be mea-
sured meaningfully if cells get the same MTT dose. Mus-
cle grafts have a more complex cellular structure than a 
cellular monolayer, which reduces the reproducibility of 
MTT assay.
Samples of human muscle tissue incubated for 72 h 
showed the highest activity, but such a protocol is not 
acceptable for the expedited ex vivo gene therapy within 
a period shorter than two hours. By comparing the re-
sults of the shorter transduction periods, we accepted 
30 minutes as the optimal time. The results obtained for 
this time period did not significantly differ from the lon-
ger transduction time (60 minutes) and were significant-
ly higher compared with the shorter transduction time 
(15 minutes). The usual duration of orthopedic surger-
ies that need bone regeneration enhancement is from 
60 minutes to several hours, so the use of gene therapy 
would not prolong the whole surgery, and thus would 
not increase the risk of complications associated with 
longer operating hours (infections, anesthesia complica-
tions, etc).
The addition of positive La3+ and Ca2+ ions did not improve 
transduction, probably because their effect was disabled 
by high dose of adenoviral vector. For viral particles and 
ions, it is more difficult to penetrate tissues than to pene-
trate monolayer cells. Phosphate precipitates with adeno-
viruses can reach the cells located on the surface of treat-
ed tissue, but the proportion of these cells is too small to 
cause an overall viral infection. In addition, effects of La3+ 
are particularly strong at low viral doses (100 viral parti-
cles or ~ 1 PFU per cell). However, when a high dose of 
50 000 viral particles per cell is used, the effect is decreas-
ing (21). Since our viral dose was 108 PFU, it is reasonable 
to conclude that the high viral dose decreased La3+ /
Ca2+ influence.
The absolute values of the BMP expression rapidly in-
creased in transduced muscles, peaked on day 12, and 
gradually decreased thereafter. The bone healing process 
lasts several weeks, and biological factors such as BMP-2 
do not have to be permanently expressed. Future studies 
should monitor the duration of the episomal transgene 
expression, determine the time of decline in the quanti-
ty of expressed BMP-2, and assess which length and ex-
tent of BMP-2 expression is required for successful bone-
formation. Earlier research on immunosuppressed Fischer 
rats found that a bone defect rapidly healed when autolo-
gous muscle tissue transduced with Ad.BMP-2 was used, 
although BMP-2 production was only in nanograms and 
lasted 1 to 3 weeks (30). The transplanted graft’s mechani-
cal strength after ACL reconstruction within the bone tun-
nel is lowest around the sixth week of the postoperative 
period, which is a specificity of healing in the bone tun-
nel (31). It is important that biological signals that stimu-
late osteogenesis persist during this period, so the actual 
clinical effect of our method needs to be confirmed by fur-
ther research. Moreover, further research should examine 
the osteogenic potential of the simultaneous use of two or 
more molecules on muscle cells (for example basic fibro-
blast growth factor and BMP-2 on bone marrow-derived 
stem cells) (32).
RUNX2 regulates osteogenic development (33) and osteo-
blast differentiation (34,35), and induces the expression of 
osteogenic genes during osteoblast maturation (36). It is 
the first transcription factor needed to determine osteo-
blast presence (33). In our study, RUNX2 was expressed 
both in non-transduced and transduced muscles, how-
ever its expression in transduced muscle was significantly 
higher at both measurement points. No difference in the 
expression was observed between days 14 and 21. The rea-
son could be a sufficient long-lasting effect of BMP-2 on 
osteoprogenitor cells and their orientation toward imma-
ture osteoblasts throughout all three weeks. A study on ge-
netically transduced rat muscle tissue using Ad.BMP-2 also 
showed significant RUNX2 expression during 20 days (18).
BSP is a marker of osteoblast differentiation (37). In our 
study, gene expression of BSP marker was present in trans-
duced and non-transduced muscles throughout the mon-
itoring period. The BSP expression in transduced muscle 
on day 14 was significantly increased compared with the 
expression in non-transduced muscles. Increased BSP ex-
pression in transduced muscles indicates osteoblast matu-
ration and orientation of muscle tissue toward the bone 
tissue production.
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DMP1 is an extracellular matrix protein important for prop-
er bone mineralization (38,39). Although all tested samples 
expressed DMP1, transduced specimens showed signifi-
cantly higher DMP1 expression than non-transduced spec-
imens. Also, transduced muscles showed 4 times higher 
expression on day 21 compared to day 14. The result sug-
gests that a period of 3 weeks is sufficient for a success-
ful transition from the osteoprogenitor to the osteocyte 
phase following the optimal transduction protocol of hu-
man muscle tissue transduced with recombinant adeno-
viral vector BMP-2. In this study, all human muscle tissue 
specimens were kept in an osteogenic differentiation me-
dium and showed basal expression of osteogenesis mark-
ers. This result confirms osteogenic differentiation poten-
tial of standard osteogenic differentiation medium on 
fresh human muscle after in vitro cultivation (24).
As expected, non-transduced muscles expressed COL-I due 
to basal osteodifferentiation of muscle tissue in the osteo-
genic medium, but the expression was significantly higher 
in transduced muscles, which corresponds to intensified 
expression of osteogenic markers in these tissues.
The main limitations of this preclinical proof-of-concept 
study are the small number of patients used per group, in-
sufficient statistical power to detect statistical significance 
for some findings, and the fact that the study was per-
formed in controlled laboratory conditions without con-
sidering the interactions and mechanical forces within a 
living organism. For this study to be translated into clinical 
practice, additional well-designed studies and clinical trials 
should be carried out, as gene therapy is still viewed as un-
safe and risky. Further studies will require close collabora-
tion between scientists and clinicians.
In conclusion, we accelerated the process of ex vivo BMP-2 
gene transfer to the hamstrings tendons muscle remnants, 
which facilitates its clinical application for improving intra-
osseous bone-tendon healing after the ACL reconstruc-
tion. The 30-minute transduction protocol should be veri-
fied in in vivo research to bring it closer to clinical practice.
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